Cancer drug combo shows promise for patients resistant to standard treatments
The study helps explain the biological reasons behind the better outcomes of this new drug combination, according to Tyner, and sets the stage for clinical trials with real patients.
CLICK HERE FOR MORE HEALTH STORIES
The drug, which was approved by the Food and Drug Administration in 2019, is often combined with azacitidine, a different cancer medication. Resistance to treatment, even with this duo, remained nearly universal.
“Unfortunately, almost everyone will eventually have drug resistance,” Tyner said in the press release.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“This regimen has improved initial response rates and quality of life, but the five-year survival rate for AML is still only about 25% to 40%. We have a lot of work to do,” he added.
The team says it does not yet have data for clinical activity in AML patients, other than some reported anecdotal cases. (iStock)
While the data strongly suggest that this new drug should be tested in clinical trials, the team says it does not yet have data for clinical activity in AML patients, other than some reported anecdotal cases.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“So, the biggest limitation is also our desired next step — of testing this new drug combination in clinical trials,” Tyner said.
Fox News Digital reached out to manufacturers of venetoclax requesting comment.
Article source: https://www.foxnews.com/health/cancer-drug-combo-shows-promise-patients-resistant-standard-treatments